Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BDTX
BDTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BDTX News
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
6d ago
NASDAQ.COM
Black Diamond Therapeutics Reports Positive Clinical Results
May 22 2026
NASDAQ.COM
Black Diamond Therapeutics Reports Positive Phase 2 Trial Results for Silevertinib
May 21 2026
Newsfilter
HCW Biologics Stock Surges 129% Amid Concerns
May 21 2026
NASDAQ.COM
Biotech Stocks Surge Significantly
May 20 2026
NASDAQ.COM
Black Diamond Therapeutics Q1 Earnings Beat Expectations
May 07 2026
seekingalpha
Black Diamond Therapeutics Q4 2025 Financial Analysis
Mar 16 2026
seekingalpha
Growth Prospects for the EGFR-NSCLC Market Analyzed
Feb 11 2026
Newsfilter
PayPal Analyst Changes Stance; Check Out Thursday's Top 5 Downgrades
Dec 04 2025
Benzinga
Black Diamond's Lung Cancer Treatment Demonstrates 60% Response Rate in Phase 2 Results
Dec 03 2025
Benzinga
US Stocks Show Varied Performance; Dollar Tree Reports Positive Earnings
Dec 03 2025
Benzinga
Black Diamond Reports 60% ORR for Silevertinib in NSCLC Patients
Dec 03 2025
Globenewswire
Black Diamond Therapeutics Reports 60% ORR for Silevertinib in NSCLC Patients
Dec 03 2025
Newsfilter
Black Diamond to Showcase Phase 2 Results of Silevertinib for Non-Small Cell Lung Cancer Today
Dec 03 2025
NASDAQ.COM
Black Diamond Therapeutics to Present Phase 2 Trial Results on December 3
Dec 02 2025
Globenewswire
Black Diamond Therapeutics to Present Phase 2 Trial Results on December 3, 2025
Dec 02 2025
Newsfilter
Show More News
